Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies

BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies

US Patent 12263203 · Granted Apr 1, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Monoclonal antibodies against IgV domain of B7-H3 and uses thereof2025
Antibodies to human B7x for treatment of metastatic cancer2025
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formul2024
Monoclonal antibodies against human tim-32024
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formul2022
HHLA2 as a novel inhibitor of human immune system and uses thereof2022
TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for 2021
B7X and its derivatives for treating and preventing cardiovascular disease2020
TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for 2019
HHLA2 as a novel inhibitor of human immune system and uses thereof2018
Antibodies to human B7x for treatment of metastatic cancer2016